Akèy › Maladi selil fòs › Maryland
Etid klinik pou Maladi selil fòs nan Maryland
17 etid pou Maladi selil fòs ap chèche patisipan nan sit nan Maryland.
Vil nan Maryland
Tèks ofisyèl etid la (Anglè)
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 70 · Tout sèks · Mizajou Oct 2, 2026 · NCT03937817Blood Sampling for Research Related to Sickle Cell Disease
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 100 · Tout sèks · Mizajou Sep 29, 2026 · NCT00542230Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 1 bonè
Laj 18 a 100 · Tout sèks · Mizajou Sep 28, 2026 · NCT06313398A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
- The Johns Hopkins University School of Medicine, Baltimore
Ap rekriteFaz 3
Laj 12 a 100 · Tout sèks · Mizajou Sep 28, 2026 · NCT06439082Dietary Intake and Dietary Behaviors in Adults With Sickle Cell Disease
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyon
Laj 18 a 120 · Tout sèks · Mizajou Sep 18, 2026 · NCT05170412Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 1
Laj 18 a 65 · Tout sèks · Mizajou Sep 17, 2026 · NCT05904093Study to Understand the Genetic Risk of Developing an Immune Response After Blood Transfusions Among Individuals With Sickle Cell Disease
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyon
Laj 2 a 99 · Tout sèks · Mizajou Sep 11, 2026 · NCT06944067SCD Stem Cell Mobilization and Apheresis Using Motixafortide
- National Heart, Blood and Lung Institute-Cellular and Molecular Therapy Branch, Bethesda
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT06442761Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 1/2
Laj 4 a 65 · Tout sèks · Mizajou Sep 4, 2026 · NCT07599176Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 1
Laj 18 a 90 · Tout sèks · Mizajou Aug 24, 2026 · NCT07566494A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
- Local Institution - 0064, Baltimore
Ap rekriteFaz 1/2Volontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT06481306ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
- Johns Hopkins University Hemophilia Treatment Center, Baltimore
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Aug 17, 2026 · NCT04398628Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
- University of Maryland, Baltimore
Ap rekriteFaz 2
Laj 12 ak plis · Tout sèks · Mizajou Aug 14, 2026 · NCT06699849Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
- Center for Cancer and Blood Disorders, Bethesda
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT07224360The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
- University of Maryland School of Medicine - Baltimore- Site Number : 8400041, Baltimore
Ap rekriteFaz 3
Laj 10 a 65 · Tout sèks · Mizajou Jul 29, 2026 · NCT06975865Cooperative Assessment of Late Effects for SCD Curative Therapies
- Johns Hopkins Hospital, Baltimore
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyon
Laj 4 a 65 · Tout sèks · Mizajou Jul 27, 2026 · NCT05153967Virtual Reality Devices as an Adjunct to Usual Care for Patients With Sickle Cell Disease Experiencing Vaso-Occlusive Crises
- University of Maryland Medical Systems, Baltimore
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Dec 24, 2025 · NCT06184126Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.